Drugs in Dev.
Dermatology
Phase III
Canada 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CTX-101
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Ferndale Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Crescita Reports Topline Results from Two Pivotal Clinical Studies
Details : Both studies of CTX-101 met the primary endpoint for psoriasis, CTX-101 is a topical formulation utilizing a corticosteroid in combination with our patented MMPE technology
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : CTX-101
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Ferndale Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
Details : IDP-126 is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 02, 2020
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
Details : IDP-126 is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 02, 2020
Lead Product(s) : IDP-126
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDP-120 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2018
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDP-120 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2018
Lead Product(s) : IDP-120
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDP-123 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2017
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDP-123 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2017
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDP-124 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 23, 2017
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDP-124 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2016
Lead Product(s) : IDP-124
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : IDP 121
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Details : IDP 121 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 16, 2016
Lead Product(s) : IDP 121
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
